Brief: Mabpharm Says Approval From NMPA On New Drug Application Of Cmab008 (Infliximab For Injection)
14/07/2021 15:18
July 14 (Reuters) - Mabpharm Ltd 2181.HK :
* MABPHARM LTD - APPROVAL FROM NMPA ON NEW DRUG APPLICATION
(NDA)
OF CMAB008 (INFLIXIMAB FOR INJECTION)
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008